Panagiota Tsiatsiou: Tissue Factor Biomarkers Reveal Persistent Procoagulant Activity During Combined Androgen Blockade in Prostate Cancer
Panagiota Tsiatsiou, Consultant Biopathologist and Microbiologist in the Laboratory Medicine Department at AHEPA University Hospital, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Journal of Thrombosis and Thrombolysis, adding:
“New publication: ‘Tissue Factor-Related Biomarkers During Combined Androgen Blockade in Patients with Prostate Cancer,’ Journal of Thrombosis and Thrombolysis,
2026.
The study evaluated tissue factor (TF) and microparticle-associated TF activity in men with prostate cancer undergoing combined androgen blockade.
Circulating TF levels were elevated at baseline and increased further after treatment, indicating a persistent procoagulant profile that routine coagulation parameters (PT, APTT,
fibrinogen, D-dimer) did not reflect.”
Title: Tissue Factor-Related Biomarkers During Combined Androgen Blockade in Patients with Prostate Cancer: A brief report
Authors: Athanasios Klampatsas, Panagiota Tsiatsiou, Paraskevoula Koutra, Dimitrios A. Tsakiris, Maria Papaioannou, Lemonia Skoura, Georgios Dimitriadis
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 4, 2026, 12:45Seema Dawood: Abnormal Nuclear Morphology of Neutrophil
-
Jul 4, 2026, 12:34Omar Adwan: Are You Following Proper Phlebotomy Technique?
-
Jul 4, 2026, 12:24Gabriela Hobbs: Outcomes of MPN Patients with Concurrent Driver Mutations
-
Jul 4, 2026, 12:04Lara Bloom: Building Momentum for Rare Diseases
-
Jul 4, 2026, 11:52Heghine Khachatryan: A Valuable Educational Resource on Inhibitor Development
-
Jul 4, 2026, 11:42Roshni Kulkarni: Study Underscores the Urgent Need to Prevent Postpartum Hemorrhage Deaths
-
Jul 4, 2026, 11:25Michael Cahillane: Latest Transfusion Medicine Research Takes Center Stage at ISBT Congress
-
Jul 4, 2026, 11:10Henning Nilius: Career Milestone Reached with FAMH Specialist Certification
-
Jul 4, 2026, 10:56Alec Van Gelder: Novo Nordisk Opens Global Patient Advocacy Role for Haemoglobinopathies